The content on this site is intended for healthcare professionals only
Prof Feugier speaks with ecancer at EHA 23 about results from a phase II trial of treating CLL with induction obinutuzumab and ibrutinib.
He describes how CR with undetectable residual disease (uMRD) may be associated with a longer survival in CLL.
With a manageable toxicity profile, 48% CR rate and 12.5% uMRD at 9 months, Prof Feugier describes the need for further research and further rounds of immunochemotherapy to fully induce uMRD.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
KRdc as induction therapy shows improved OS for NDMM patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Advancements in paediatric Acute lymphoblastic leukemia management
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
GIST tumours and soft tissue sarcomas
Multiple myeloma in a resource constrained setting
Relapsed refractory multiple myeloma
